

THURSDAY, NOVEMBER 9 - SATURDAY, NOVEMBER 11

A SESSIONS

Designed for healthcare professionals. CME/CE is provided unless noted otherwise. (*)

B SESSIONS

Designed for recently diagnosed patients and their caregivers.

C SESSIONS

Designed for those who have been living with PF for a while.

D SESSIONS

Designed for individuals who are not currently living with PF, such as transplant recipients and individuals who have lost a loved one.

While some sessions are tailored for attendees with specific experiences, you may attend **any** session that interests you.

REGISTRATION

7:30 A.M. - 8:00 P.M.

COMMUNITY PULMONOLOGISTS AND ILD FELLOWS (CME) 10:00 A.M 4:00 P.M. BROADWAY J	Pre-registration required
Protocol for evaluation of the patient with interstitial lung disease	Lisa Lancaster, MD
How to assess for autoimmune disease in your ILD patient	Aryeh Fisher, MD
Evaluating an occupational exposure history	Mridu Gulati, MD
MDD and an accurate diagnosis in ILD	David Lederer, MD
How to effectively read an HRCT and utilize its clues for differential diagnosis in ILD	Mary Salvatore, MD
Approach to pathological analysis of ILDs	Joyce Johnson, MD
Lunch provided	
Utility and options for lung biopsy: Emerging utility of bronchoscopic cryobiopsy	Fabien Maldonado, MD
Approved therapies for IPF: A review of the data	Sonye Danoff, MD
Safety and management of side effects of pirfenidone and nintedanib	Wendi Mason, MSN
Stem-cell and cell-based therapies in lung disease (paucity of data in just IPF)	Marilyn Glassberg, MD
Non-pharmacological management of IPF/ILD	Wendi Mason, MSN
Palliative care and hospice	Kathleen O. Lindell, PhD, RN
Evaluation for lung transplant	Tim Whelan, MD

THURSDAY, NOVEMBER 9



PATIENTS AND CAREGIVERS: LUNCH

TAKING AN ACTIVE ROLE IN YOUR IDIOPATHIC PULMONARY FIBROSIS (IPF) MANAGEMENT - PRESENTED BY GENENTECH







11:30 A.M. - 12:45 P.M. | CUMBERLAND 5

Pre-registration is required and opens at the *Summit* at 11 A.M on Thursday. Open to tracks B, C, and D only.

PATIENTS AND CAREGIVERS: INTRO TO THE PFF, NEED MEETS ACTION, AND UNDERSTANDING THE BASICS OF RESEARCH





Hal Collard, MD,

David McNinch

Panel Volunteers

PFF Ambassador,



Kevin Flaherty, MD, MS

1:00 P.M. – 4:00 P.M. | BROADWAY F

Introduction of the PFF and the Care Center Network

Research 101: Understanding the process, terminology, and definitions and how a drug is brought to market

Q&A

Break (15 minute)

Need Meets Action Part I: Overview of volunteering at the PFF

PFF Development Team and

PFF Development Team and

PRODUCTION OF THE PERSON OF

Need Meets Action Part II: Overview of effective fundraising

PFF Development Team and Panel Volunteers

Q&A

FOCUS GROUPS

1:00 P.M. - 2:00 P.M | CUMBERLAND 2 & 4

Focus Group 1 (1:00 P.M. - 2:00 P.M.)

Focus Group 2 (1:00 P.M. - 2:00 P.M.)

Pre-registration required

Pre-registration required

FOCUS GROUPS

2:00 P.M. - 5:00 P.M | CUMBERLAND 2 & 4

Focus Group 3 (2:00 P.M. - 3:00 P.M.)

Focus Group 4 (2:00 P.M. - 3:00 P.M.)

Focus Group 5 (2:00 P.M. - 3:00 P.M.)

Pre-registration required

Pre-registration required

Pre-registration required

WELCOME RECEPTION AND POSTER PRESENTATION:

SPONSORED BY HALES FAMILY FOUNDATION

A







FRIDAY, NOVEMBER 10



REGISTRATION 7:00 A.M. - 8:00 P.M.

BREAKFAST 7:00 A.M. - 8:00 A.M.

DI ENADY CECCION I DECIMICE OF CENETICS AND DEDCOMALIZED	
PLENARY SESSION I: PROMISE OF GENETICS AND PERSONALIZED MEDICINE IN PF (CME)	A B C D
8:00 A.M. – 10:00 A.M. BROADWAY E,F	
National Heart, Lung and Blood Institute (NHLBI) support for personalized therapy in lung disease	Jim Kiley, PhD
State-of-the-art approaches to genetic discovery in complex disease	Jeff Trent, PhD
Current status of clinical genetic testing in ILD	Jim Loyd, MD
A genetic counselor's perspective: Impact of genetic information for	Janet Talbert, MS, CGC
patients and families	
Panel discussion	Jim Kiley, Jeff Trent, Jim Loyd, Janet Talbert, Jane Nelson, Heather Kagel
30 minute break and networking	All
SESSION 1A: ENVIRONMENTAL INFLUENCES(CME) 10:30 A.M 12:15 P.M. BROADWAY E	A
Poster winner: Abstract talk I	TBA
The microbiome in IPF	Phil Molyneaux, PhD
Gastroesophageal Reflux Disease (GERD) in ILD	Ganesh Raghu, MD
Sleep apnea in ILD	Lisa Lancaster, MD
Autoimmune mechanisms of pulmonary fibrosis: CTD-ILD	Aryeh Fisher, MD
SESSION 1B, C, D: KIDBILLY MUSIC - PRESENTED BY GENENTECH	B C D

10:30 A.M. - 12:15 P.M. | BROADWAY G,H,J

Perspectives from All: Songwriting for team-building, networking, and emotional healing

KidBilly Music

SESSION 2A: GENETICS OF ILD (CME) 1:15 P.M 2:50 P.M. BROADWAY E	A
Poster winner: Abstract talk II	TBA
Spectrum of telomere-related ILD	Mary Armanios, MD
Progression and outcome of telomere-related ILD	Christine Garcia, MD

^{*} CME credit not provided

3:15 P.M. – 4:55 P.M. | BROADWAY K



FRIDAY, NOVEMBER 10

New genes associated with familial ILD Jon Kropski, MD * Results of whole genome sequencing in sporadic IPF Brian Yaspan, PhD **SESSION 2B: UNDERSTANDING ILD AND IPF** В 1:15 P.M. – 2:55 P.M. | BROADWAY K Part I: Overview of ILD, IPF, and connective tissue disease Kristin Highland, MD Mary Beth Scholand, MD Part II: Understanding your test results: HRCT, 6MWT, PFTs, and oximetry ΑII Q&A **SESSION 2C: QUALITY OF LIFE: NEXT STEPS** (C) 1:15 P.M. - 2:55 P.M. | BROADWAY G,H Josh Mooney, MD, MS Part I: Evaluation for lung transplantation Linda Manning, MD Part II: Using mindfulness for stress management in chronic disease Wendi Mason, MSN Part III: Treatment of cough Q&A SESSION 2D: CALL TO ACTION, PART I 1:15 P.M. – 2:50 P.M. | BROADWAY J Kathleen O. Lindell, PhD, Part I: Transitioning after the loss of a loved one, after a transplant (two roundtables) RN, John Mulder Bill Schmidt, Kate Gates Part II: How to participate in legislative advocacy ΑII **Group Activity** ΑII 30 minute break and networking **SESSION 3A: DISEASE MECHANISMS I (CME)** 3:15 P.M. - 4:50 P.M. | BROADWAY E Poster winner: Abstract talk III Paul Wolters, MD Pre-clinical modeling of telomerase deficiency Victor Thannickal, MD Role of aging and senescence in IPF Tushar Desai, MD, MPH Epithelium as the guardian of the lungs: Response to injury Paul Noble, MD Mechanism of alveolar epithelial cell renewal: Impact on ILD SESSION 3B: OXYGEN THERAPY, PULMONARY REHABILITATION, AND SYMPTOM MANAGEMENT



FRIDAY, NOVEMBER 10

Part I: Living with oxygen therapy and PF

» Overview of various types of POCs, compressed gas units, trans-fill systems, and backpacks

Susan Jacobs, RN, M

» How can I be active and travel with O2 (MedJet and other emergency travel services)?

Part II: Pulmonary rehab: What is it and how can it help me?

Trina Limberg, BS, RRT

Part III: Symptom management: Cough, dyspnea and fatigue Mary Strek, MD

Q&A

SESSION 3C: WHAT'S IN THE PIPELINE? CURRENT CLINICAL TRIALS, POTENTIAL THERAPIES, AND HOW THE PROCESS WORKS



3:15 P.M. - 4:55 P.M. | BROADWAY G,H

Part I: Understanding how clinical trials work and the therapeutic process to bring a drug to market

Bill Bradford, MD, PhD

Part II: Current clinical drug trials in the pipeline for IPF and PF, and an overview of potential therapies moving forward

SESSION 3D: CALL TO ACTION PART II: HOW TO HOST A

Gregory Cosgrove, MD

Q&A

FUNDRAISING EVENT

D

3:15 P.M. - 4:55 P.M. | BROADWAY J

How to host a fundraising event PFF Development Team

NETWORKING COCKTAIL HOUR

5:30 P.M. - 6:30 P.M. | PREFUNCTION AREA

A







NETWORKING DINNER WITH ENTERTAINMENT BY KIDBILLY MUSIC AND THE PFF COMMUNITY, PRESENTED BY GENENTECH

6:30 P.M. - 9:00 P.M. | BROADWAY E









SATURDAY, NOVEMBER 11



REGISTRATION 7:00 A.M. - 4:00 P.M.

BREAKFAST 7:00 A.M. - 8:00 A.M. | BROADWAY E

PLENARY SESSION II: MAXIMIZING THE IMPACT OF AVAILABLE
THERAPIES IN IPF (CME)









8:00 A.M. - 10:00 A.M. | BROADWAY E,F

KEYNOTE: Re-thinking clinical trials in PF

PFF Care Center Network and PFF Patient Registry

Improving care for PF patients and adherence to treatment plans: A physician

family member's perspective

PANEL DISCUSSION: Opportunities and obstacles to provide optimal care for

PF in 2017

Gordon R. Bernard, MD

Kevin Flaherty, MD, MS

Jason Martin, MD

Gordon R.Bernard, Kevin

Flaherty, Jason Martin, Greg Cosgrove, Maryluz Fuentes,

MD, Carolyn Adams-Duda

ΑII

30 minute break and networking

10:30 A.M. - 12:15 P.M. | BROADWAY E

SESSION 4A: DIAGNOSIS OF IPF (CME)

Poster winner: Abstract talk IV

Advances in HRCT imaging, quantitative HRCT imaging in IPF trials and

clinical care

New approaches to diagnosis: Potential role for cryobiopsy

Pre-clinical ILD

Lessons from at-risk cohorts



TBA

Jonathan Goldin, MD, PhD

Fabien Maldonado, MD

Gary M. Hunninghake, MD

Tim Blackwell, MD

SESSION 4B, C, D: BASICS OF GENETICS AND WHAT WE KNOW ABOUT STEM CELL THERAPY

10:30 A.M. - 12:15 P.M. | BROADWAY F

Part I: Genetics 101 in IPF

Part II: Stem cell therapies and biotourism

» What is stem cell therapy and what is it approved for?

Stem cell centers in the community

Part III: Clinical trials with stem cells for ILD

Q&A









Sonye Danoff, MD

Marilyn Glassberg, MD

ΑII



SATURDAY, NOVEMBER 11

LUNCH AND NETWORKING (B, C GROUPS)	BC
12:15 P.M 1:15 P.M. BROADWAY E	
Lunch with people who live in your region	
LUNCH AND NETWORKING (D GROUP) 12:15 P.M 2:00 P.M.	D
Lunch off-site	PFF Staff
SESSION 5A: THERAPEUTICS (CME)	
1:15 P.M 2:50 P.M. BROADWAY E	A
Poster winner: Abstract talk V	TBA
Drug development in IPF: What is on the horizon	Andy Limper, MD
* Stem cell therapies: Real possibility or not?	Ramona Doyle, MD
Personalized medicine in IPF, integrating genetics in clinical trials	Imre Noth, MD
Role of biomarkers in diagnosis and treatment	Naftali Kaminski, MD
SESSION 5B, C: APPROVED THERAPIES FOR IPF AND DIAGNOSIS	
AND TREATMENT OF COMORBIDITIES IN ILD	BC
1:15 P.M 2:50 P.M. BROADWAY F	
Part I: Overview of pirfenidone and nintedanib	Joyce Lee, MD
Part II: Adherence to treatment plans: Safety and management of side effects with pirfenidone and nintedanib	Wendi Mason, MSN
Part III: How to qualify for reduced payment plans	Anne Turner, RN, BSN
Breakout Discussions: Diagnosis and Treatment of Comorbidities	
Obstructive sleep apnea (OSA)	Lisa Lancaster, MD
Gastroesophageal Reflux Disease (GERD)	Wendi Mason, MSN
Scleroderma	Kristin Highland, MD
Sarcoidosis	Bob Baughman, MD
SESSION 5D: CALL TO ACTION PART III: WHAT'S NEXT	(D)
2:30 P.M 4:00 P.M. BROADWAY J	

2:30 P.M. - 3:30 P.M | CUMBERLAND 2 &4

^{*} CME credit not provided

PFF SUMMIT

SATURDAY, NOVEMBER 11

Focus group 6 (2:30 P.M. - 3:30 P.M.)

Focus group 7 (2:30 P.M. - 3:30 P.M.)

Pre-registration required Pre-registration required

BREAK AND NETWORKING (GROUPS A, B, C)

2:50 P.M. - 3:15 P.M.







SESSION 6A: DISEASE MECHANISMS II (CME)

3:15 P.M. - 4:50 P.M. | BROADWAY E

Poster Winner: Abstract Talk VI

Lessons from other rare genetic diseases - Hermansky-Pudlak Syndrome

Mechanoregulation of matric deposition and fibrosis progression

Epithelial-fibroblast interactions in lung fibrosis

Immune/inflammatory cells in IPF

TBA

Lisa Young

Dan Tschumperlin, PhD

Kevin Kim, MD

Erica Herzog, MD, PhD

SESSION 6B, C: ROUNDTABLE DISCUSSIONS

3:15 P.M. - 4:50 P.M. | BROADWAY F

В



Caregiver burnout

How to prepare for an effective clinical visit with your doctor

Depression and anxiety in chronic disease

Palliative and hospice care

How to participate in legislative advocacy

John Mulder

David Lederer, MD, Michele Peters

Jim Jackson, PhD

Kathleen O. Lindell, PhD, RN

Bill Schmidt, Kate Gates